Journals / Journal of the Turkish-German Gynecological Association / 2005 / Cilt: 6 - Sayı: 2

Menorajide levonorgestralli intrauterin sistemin etkinliği: Bir yıllık sonuçlarımız

Efficacy of levonorgestrel releasing intrauterine system in menorrhagia: A one-year follow-up study

Pages
130–133
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Hemoglobin levels increased from a mean value of 1O.71±1.97 to 13.31±1.34 g/dl (P

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To assess the efficacy of the levonorgestrel intrauterine system in the treatment of menorrhagia.
📊
Key Findings & Data:Results: At the end of the first year, 33 women (68.75%) were reached and the continuation rate was 75.75%.
💡
Conclusion & Impact:Hemoglobin levels increased from a mean value of 1O.71±1.97 to 13.31±1.34 g/dl (P
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To assess the efficacy of the levonorgestrel intrauterine system in the treatment of menorrhagia. Materials and Methods: Forty-eight premenopausal women, attending to our gynecology clinic with the complaint of me-norrhagia were enrolled into the study. Clinical assessment tools of menstrual bleeding such as endometrial thickness, hemoglobin and serum ferritin levels were measured both before (Group A) and one year (Group B) after the insertion of the intrauterine device. Paired samples t test was used for comparing the differences between groups. Results: At the end of the first year, 33 women (68.75%) were reached and the continuation rate was 75.75%. While the mean number of pads used daily during menstruation in Group B patients decreased, the hemoglobin and serum ferritin levels increased significantly. Hemoglobin levels increased from a mean value of 1O.71±1.97 to 13.31±1.34 g/dl (P

Özet

Amaç: Levonorgestrelli intrauterin sistemin menoraji tedavisinde etkinliğini araştırmak. Materyal ve Metot: Menoraji yakmmasıyla Jinekoloji kliniğimize başvuran 48 premenopozal olgu çalışmaya dahil edildi. Menstrüel kanama miktarının klinik değerlendirilmesinde kullanılan parametrelerden olan endometriyal kalınlık, hemoglobin ve serum ferritin seviyeleri hem uygulamadan önce (Grup A) hem de intrauterin araç uygulandıktan bir yıl sonra (Grup B) ölçüldü. Gruplar arasındaki farkın karşılaştırılmasında paired samples t test kullanıldı. Sonuçlar: Birinci yılın sonunda 33 hastaya (%68.75) ulaşılabildi ve tedaviye devam oranı %75.75 idi. Grup B hastalarda menstrüasyon döneminde kullanılan ortalama günlük ped sayısı azalırken, hemoglobin ve serum ferritin seviyelerinde anlamlı artışlar saptandı. Hemoglobin ortalama değeri 10.71±1.97 g/dl'den 13.31 + 1.34 g/dl'ye (P

🔖

Cite This Article

KAYIKÇIOĞLU, F., HABERAL, A., GÜNEŞ, M., KAPLAN, M., ÖZDEĞİRMENCİ, Ö. (2022). Menorajide levonorgestralli intrauterin sistemin etkinliği: Bir yıllık sonuçlarımız. Journal of the Turkish-German Gynecological Association, Cilt: 6 - Sayı: 2, 130–133. https://ajindex.com/articles/568049

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Coulter A, Bradlow J, Agass M, Martin-Bases C, Tulloch A. Outcomes of referrals to gynecology outpatient clinics for menstrual problems: an audit of general practice records. Br J Obstet Gynaecol 1991;98:789-96
  2. Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S, Kivelâ A, Kujansuu E, Vuorma S, Yliskoski M, Paavonen J. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomized trial. Lancet 2001;357:273-7
  3. Lethaby AE, Cooke I, Rees M. Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding. (Cochrane Review). In: The Cochrane Library, Issue3, 2000
  4. Luukkainen T. The levonorgestrel intrauterine system: therapeutic aspects. Steroids 2000;65:699-702
  5. Sivin I. Potential benefits in developing countries through use of the levonorgestrel-releasing intrauterine system. Gynaecology Forum 1998;3(3):23-5
  6. Kelleher C, Braude P. Recent advances, Gynaecology. BMJ 1999;319:689-92
  7. Andersson K. Intrauterine release of levonorgestrel-a contraceptive and therapeutical system. Gynaecology Forum 1998;3(3):3-5. e Istre O, Trolle B. Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. Fertil Steril 2001;76:304-9. o MacDonald R, Phipps J, Singer A. Endometrial ablation: a safe procedure. Gynecol Endoscopy 1992; 1:7-9. 10 Bongers MY, Mol BWJ, Brölmann HAM. Current treatment of dysfunctional uterine bleeding. Maturitas 2004;47:159-74. U Luukkainen T, Toivonen J. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Contraception 1995;52:269-76
  8. Faundes A, Alvarez F, Brache V, Tejada AS. The role of the levonorgestrel IUD in the prevention and treatment of iron deficiency anemia during fertility regulation. Int J Gynecol Obstet 1988;26:429-33
  9. Stewart A, Cummins C, Gold L, Jordan R, Phillips W. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. Br J Obstet Gynaecol 2001;108:74-86
  10. Fong YF, Singh K. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system. Contraception 1999;60:173-5
  11. Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril 2003;79(5): 1194-8
  12. Soysal S, Soysal